tbuckley/cabot-search huggingface dataset:
Increase in stabbing.
Journal: BMJ (1967)

Leading ArticlesBRITIHL 813malaise, pyrexia, and possibly upper respiratory infection, and then over two or three days the patient becomes confused and develops headache of moderate severity, high pyrexia, and slight neck stiffness.Convulsions, which may be focal, often occur and a moderate hemiparesis may develop at the same time or later.The picture is that of a rapidly expanding cerebral lesion, though clinical localization is sometimes difficult and the systemic signs are unusual.The cerebro- spinal fluid has a raised cell count (60 to 300 leucocytes/ cu.mm.), perhaps a number of red cells, and a high protein but normal sugar content.If the centrifuged deposit is
Author Index Vol. 73, 2004
Authors: Jane Irvine, Zachary M. Shnek, Donna E. Stewart, E. Micali, C. Giorgianni, F. Munaò, R. Brecciaroli, L. Salmaso, D. Germanò, Madelon Y. Bolling, Robert J. Kohlenberg, Nicoletta Sonino, Tommi Tolmunen, Jukka Hintikka, Anu Ruusunen, Sari Voutilainen, Antti Tanskanen, Veli-Pekka Valkonen, Heimo Viinamäki, George A. Kaplan, Jukka T. Salonen, Giovanni A. Fava, Jenny Guidi, Secondo Fassino, Paolo Leombruni, Federico Amianto, Giovanni Abbate-Daga, C. Abbate, Anne-Mette Hvas, Svend Juul, Per Bech, Ebba Nexø, Roland von Känel, Brigitte M. Kudielka, Renate Schulze, Marie-Louise Gander, Joachim E. Fischer, Erwin Lemche, Gisela Klann-Delius, Rainer Koch, Peter Joraschky, Bernd Löwe, Kerstin Gräfe, Stephan Zipfel, Steffen Witte, Bernd Loerch, Wolfgang Herzog, Sherry L. Grace, Susan E. Abbey
Journal: Psychotherapy and Psychosomatics (2004)
A BILL FOR THE REGULATION OF EXPERT TESTIMONY.
Journal: JAMA (1992)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The appropriateness of use of percutaneous transluminal coronary angioplasty in New York State
Authors: L. H. Hilborne
Journal: JAMA (1993)

<h3>Objective.</h3> —To determine the appropriateness of use of percutaneous transluminal coronary angioplasty (PTCA) in New York State. <h3>Design.</h3> —Retrospective randomized medical record. <h3>Setting.</h3> —Fifteen randomly selected hospitals in New York State that provide PTCA. <h3>Patients.</h3> —Random sample of 1306 patients undergoing PTCA in New York State in 1990. <h3>Main Outcome Measures.</h3> —Percentage of patients who underwent PTCA for indications rated appropriate, uncertain, and inappropriate. <h3>Results.</h3> —The majority of patients received PTCA for chronic stable angina, unstable angina, and in the post—myocardial infarction period (up to 3 weeks). Fifty-eight percent of PTCAs were rated appropriate; 38%, uncertain; and 4%, inappropriate. The inappropriate rate varied by hospital from 1% to 9% (<i>P</i>=.12); the uncertain rate, from 26% to 50% (<i>P</i>=.02); and the combined inappropriate and uncertain rate, from 29% to 57% (<i>P</i>&lt;.001). There was no difference in appropriateness when the institutions were grouped by volume (fewer than 300 procedures annually or at least 300 procedures annually), location (upstate vs downstate), or by teaching status. <h3>Conclusions.</h3> —Few PTCAs were performed for inappropriate indications in New York State. However, the large number of procedures performed for indications that were rated uncertain as to their net benefit requires further study and justification at both clinical and policy levels. (<i>JAMA</i>. 1993;269:761-765)
SP0040 New Antivirals for Extrahepatic Manifestations of Hepatitis C Virus: The Model of Mixed Cryoglobulinemia Vasculitis
Authors: P. Cacoub
Journal: Annals of the Rheumatic Diseases (2016)

Mixed cryoglobulinemia vasculitis (Cryovas) is a small vessel vasculitis involving mainly the skin, the joints, the peripheral nerve system and the kidneys. Hepatitis C virus (HCV) infection is the cause of Cryovas in about 80% of cases. The disease expression is variable, ranging from mild symptoms (purpura, arthralgia) to fulminant life-threatening complications (glomerulonephritis, widespread vasculitis). Most HCV-Cryovas manifestations respond to clearance of HCV during antiviral therapy. Patients who relapse for HCV infection after responding to antiviral therapy usually relapse for the Cryovas with the return of viremia. Interferon alpha-based therapy has long been the cornerstone of HCV-Cryovas treatment. In the early 20109s, use of triple HCV therapy with pegylated-interferon/ribavirin and a direct antiviral agent (DAA, boceprevir or telaprevir) led to improved rates of sustained virological response and Cryovas remission. However, frequent side effects limited the use of such combinations. During the last two years, all oral interferon-free, DAA regimens have been used in HCV-Cryovas, associated with very high rates of sustained virological response and clinical remission of the Cryovas, and few toxicities. In daily practice, HCV-Cryovas patients with mild to moderate disease should be given an optimal all oral, interferon-free, DAA regimen. For patients with severe vasculitis control of disease with rituximab, with or without plasmapheresis, is required while starting optimal antiviral therapy. Other immunosuppressants should be given only in case of refractory forms of HCV-Cryovas. <h3>Disclosure of Interest</h3> P. Cacoub Shareholder of: ILTOO pharma, Speakers bureau: Abbvie, Astra Zeneca, Bayer, Boehringer Ingelheim, Gilead, Glaxo Smith Kline, Janssen, Merck Sharp Dohme, Pfizer, Roche, Servier, Vifor.
Massachusetts Medical Society
Authors: John Figgis Jewett
Journal: New England Journal of Medicine (1956)

COMMITTEE ON MATERNAL WELFAREPseudomembranous EnteritisA twenty-seven-year-old gravida III, para II, with an uneventful prenatal course was admitted to the hospital because of mild, irregular uterine contractions at term. There was no bleeding or other abnormality. After the usual preparation, the patient fell asleep for the remainder of the night. Several hours later, after a few irregular contractions but without any bleeding and with the membranes still intact, the uterus was described as "hard," and the fetal heart tones could not be heard. Pain was not severe enough to require sedation. At this point, approximately twelve hours after admission, . . .
PLoS Medicine Issue Image | Vol. 1(2) November 2004
Journal: PLoS Medicine (2004)

This work is from "Doilies," a series of framed sculptures, in which each pattern is based on the structure of a different virus. The designs are created using machine embroidery software, and the resulting images are stitched onto water-soluble fabric by a computerized sewing machine. When the fabric is dissolved, the remaining threads form a doily-like pattern. The lace doily has traditionally been used to present romanticized designs and motifs from nature and domesticity. These objects would be heirlooms, handed down from one generation to the next. The combination of the microbial images with the traditional decorative object evokes the psychological heredity of cultural fears. The series explores the domestication of microbial and biomedical imagery. Recent beauty fads, epidemics, and commercial products have brought this imagery into our living rooms, kitchens, and bathrooms. Bioterrorism, SARS, and antibacterial soaps alike have all heightened our awareness of microbial hazards. These sculptures serve as a metaphor for the way we have adapted our everyday lives to these now everyday concerns. The delicate and inviting embroidered patterns stand at odds with the unsettling truth of our collective apprehension. Laura Splan is a San Francisco-based artist. She holds a Bachelor of Fine Art from the University of California, Irvine, where she originally studied Biological Sciences, and she recently received her Master of Fine Art in Sculpture from Mills College in Oakland, California, where she complimented her studio work with an independent study in the Microbiology Department. She works with a wide range of materials and explores perceptions of beauty and horror, comfort and discomfort. Using anatomical and medical imagery as a point of departure, she explores these dualities and our ambivalence towards the human body and its biological functions. Image Credit: Laura Splan (www.laurasplan.com)
Castration of Criminals
Journal: JAMA (1934)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
High Blood Ammonia Levels Are Associated with Poor Outcome after Lung Transplantation
Journal: Annals of Internal Medicine (2000)

Summaries for Patients15 February 2000High Blood Ammonia Levels Are Associated with Poor Outcome after Lung TransplantationSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-132-4-200002150-00032 SectionsAboutFull Text ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail What is the problem and what is known about it so far?Small amounts of ammonia are normally in the bloodstream. Many serious illnesses, including liver damage, can cause blood ammonia levels to rise. High levels of ammonia can cause patients to become confused and die, if left untreated. Massively increased ammonia levels have been found in a few patients after lung transplantation, but it is unknown how often this occurs or who will develop this condition. It has been demonstrated previously that two of these patients lacked a liver enzyme that helps to metabolize ammonia.Why did the researchers ... Author, Article, and Disclosure InformationAffiliations: The summary below is from the full report titled “Fatal Hyperammonemia after Orthotopic Lung Transplantation.” It is in the 15 February 2000 issue of Annals of Internal Medicine (volume 132, pages 283-287). The authors are G.R. Lichtenstein, Y.-X. Yang, F.A. Nunes, J.D. Lewis, M. Tuchman, G. Tino, L.R. Kaiser, H.I. Palevsky, R.M. Kotloff, E.E. Furth, J.E. Bavaria, M.M. Stecker, P. Kaplan, and G.T. Berry.Summaries for Patients are a service provided by Annals to help patients better understand the complicated and often mystifying language of modern medicine.Summaries for Patients are presented for informational purposes only. These summaries are not a substitute for advice from your own medical provider. If you have questions about this material, or need medical advice about your own health or situation, please contact your physician. The summaries may be reproduced for not-for-profit educational purposes only. Any other uses must be approved by the American College of Physicians-American Society of Internal Medicine. Previousarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoFatal Hyperammonemia after Orthotopic Lung Transplantation Gary R. Lichtenstein , Yu-Xiao Yang , Frederick A. Nunes , James D. Lewis , Mendel Tuchman , Gregory Tino , Larry R. Kaiser , Harold I. Palevsky , Robert M. Kotloff , Emma E. Furth , Joseph E. Bavaria , Mark M. Stecker , Paige Kaplan , and Gerard T. Berry Metrics 15 February 2000Volume 132, Issue 4Page: 283KeywordsAmmoniaBloodHemorrhageLiverLung transplantationLungsPrimary hypertensionRespiratory system proceduresSurgeryTransplantation ePublished: 15 August 2000 Issue Published: 15 February 2000 Copyright & PermissionsCopyright © 2000 by American College of Physicians. All Rights Reserved.Loading ...
Abstract 12492: Multimodality Intravascular Imaging Assessment of Plaque Erosion vs Plaque Rupture in Patients With Acute Coronary Syndrome
Authors: Sang-Wook Kim, Hoyoun Won, Gary S Mintz, Young Joon Hong, Sung Yun Lee, Ki Seok Kim, Joo Yong Hahn, Wang Soo Lee, Seong Hyeop Hyeon, Jee Eun Kwon, Seung Yong Shin, Kwang Je Lee, Tae Ho Kim, Chee Jeong Kim
Journal: Circulation (2014)

We used optical coherent tomography (OCT) and virtual histology intravascular ultrasound (VH-IVUS) to assess culprit lesions in 146 Korean pts with acute coronary syndrome (ACS). Methods: Culprit lesion plaque rupture (PR) or plaque erosion (PE) was diagnosed with OCT; and IVUS was used to determine arterial remodeling. PE (n=56) was the presence of intracoronary thrombus attached to the luminal surface with no detectable signs of fibrous cap rupture that was seen in 90 ACS pts with PR. Positive remodeling was a remodeling index (lesion/reference EEM [external elastic membrane] area) &gt;1.05. Results: Pt age was 60±12 yrs in PR and 62±11 yrs in PE; 19% of PR vs 18% of PE were females. Overall, 25% (14/56) of PE had non-ST elevation myocardial infarction (NSTEMI) and 34% (19/56) had STEMI; conversely, 14.4% (13/90) of PR had NSTEMI and 71% (64/90) had STEMI (p&lt;0.0001). Vessel size, minimal lumen area, and lumen area at the PR or PE site were similar; however, lesion length was longer in PR. Plaque area was smaller with negative remodeling in PE while PR showed positive remodeling with a larger necrotic core area by VH-IVUS (Table). By OCT, PE were fibrotic in 50% (28/56), fibrocalcific in 16% (9/56), and lipidic in 32.1% (18/56, all but one of which was a thick cap fibroatheroma). Conclusion: Multimodality intravascular imaging with OCT and VH-IVUS showed fundamentally different pathoanatomic substrates underlying plaque rupture and erosion in Asian pts.
Surveys and Symposia
Journal: JAMA (1968)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Physical activity, physical fitness, and health: time to act
Authors: J. P. Koplan
Journal: JAMA (1989)

An increasing body of evidence suggests that physical activity and physical fitness contribute to good health. Studies have demonstrated that physical activity, be it occupational or recreational, is associated with decreased risks of coronary heart disease.<sup>1</sup>Other studies suggest that risks for colon cancer,<sup>2</sup>stroke,<sup>3</sup>and hypertension<sup>4</sup>are reduced and that exercise can assist in management of persons with diabetes,<sup>4</sup>depression,<sup>5</sup>and obesity.<sup>6</sup>Blair et al<sup>7</sup>provide evidence in this issue of<i>JAMA</i>that physical fitness is associated with lower rates of all causes of mortality as well as cardiovascular disease and cancer mortality. Physical fitness is determined by our genetics and our behavior. While we cannot change our genes, we can modify our behavior. Increased physical activity leads to improved physical fitness and to other physiological changes. It is the combination of these changes that leads to improved health. Not only is
IODINE AND ATHEROSCLEROSIS
Journal: JAMA (1935)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Phase I and biomarker study of ABT869, a multiple receptor tyrosine kinase inhibitor, in patients with refractory solid malignancies
Authors: C. I. Wong, C. H. Thng, R. Soo, C. S. Chen, N. Sukri, N. Gupta, E. McKeegan, S. C. Lee, R. Humerickhouse, B. C. Goh
Journal: Journal of Clinical Oncology (2007)

3519 Background: ABT869 is an orally administered, potent and specific inhibitor of all VEGF and PDGF family tyrosine kinases, including FLT-3, and c-kit receptors. Methods: A phase I study of ABT869 in patients with refractory solid malignancies was initiated to determine the maximum tolerable dose (MTD) of ABT869 given by continuous once-daily oral dosing; evaluate ABT869 pharmacokinetics; assess pharmacodynamic effects on plasma VEGF and circulating endothelial cells (CECs); evaluate tumor response, including an assessment of microcirculatory parameters DCE-MRI. Dose escalation was planned in dose cohorts of 3 patients each. Treatment periods (TP) were defined as 21 days and tumor assessments were performed using CT scans every 6 weeks. DCE-MRI was done at baseline, day 3 and 14 of the first cycle. Cohort expansion to 6 patients was planned if dose limiting toxicity (DLT) occurred in the first cycle of treatment, and MTD was defined as the dose at which ≥ 2/6 patients experienced DLT. Results: 21 evaluable patients (11 male, 10 female patients median age 58 range 29–76) were treated; 6 at 10mg per day, 12 at 0.25mg/kg/day and 3 at 0.3mg/kg/day. Cycle 1 DLTs included fatigue (grade(G) 3 DLT in 1 patient at 10mg), G3 foot rash, proteinuria and hypertension in 1 patient each at 0.25mg/kg/day (RPTD) and 2 patients with G3 hypertension, including G3 proteinuria in one of these patients, at 0.3mg/kg/day (MTD). Other common treatment-related adverse events at RPTD included asthenia, myalgia, mouth irritation, pneumothorax related to cavitating lung nodule in 2 patients. Pharmacokinetics of ABT869 demonstrated oral clearance of 2.8 ± 1.2 L/h, (mean ± SD, N=16) and half-life of 16.9 ± 5.0 h, with minimal drug accumulation at day 15. 2 PRs were seen in NSCLC patients and stable disease &gt; 4 TPs was observed in 12 patients, with CT scan evidence of cavitation of pulmonary disease and reduced DCE-MRI derived parameters. Mean peak plasma VEGF levels were increased significantly from baseline (p=0.031). CEPs and CECs were reduced in most patients by day 15. Conclusions: 0.25mg/kg/day is the RPTD of ABT869. Modulation of plasma VEGF, CECs and DCE MRI show drug activity consistent with antiangiogenic activity. Promising clinical activity is seen, particularly in NSCLC. No significant financial relationships to disclose.
Annales de l'Institut Pasteur, Paris
Journal: JAMA (1967)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Analysis of Pediatric Blood Lead Levels in New York City for 1970-1976
Authors: Irwin H. Billick, Anita S. Curran, Douglas R. Shier
Journal: Environmental Health Perspectives (1979)

A study was completed of more than 170,000 records of pediatric venous blood levels and supporting demographic information collected in New York City during 1970-1976. The geometric mean (GM) blood lead level shows a consistent cyclical variation superimposed on an overall decreasing trend with time for all ages and ethnic groups studied. The GM blood lead levels for blacks are significantly greater than those for either Hispanics or whites. Regression analysis indicates a significant statistical association between GM blood lead level and ambient air lead level, after appropriate adjustments are made for age and ethnic group. These highly significant statistical relationships provide extremely strong incentives and directions for research into casual factors related to blood lead levels in children.